Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction

JAMA Author Interviews
08/08/2023 18 min
Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction

Listen "Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction"

Descargar episodio Ver en sitio original

Episode Synopsis

Anthracyclines are used to treat a variety of cancers, but treatment may be limited by cardiac toxicity. JAMA Executive Editor Gregory Curfman, MD, discusses a new clinical trial on the use of atorvastatin to prevent anthracycline-induced cardiac toxicity with authors Tomas Neilan, MD, MPH, and Marielle Scherrer-Crosbie, MD, PhD. Related Content: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

More episodes of the podcast JAMA Author Interviews

From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism 30/09/2025
From the JAMA Network: AI-Based Analysis for Parkinsonism 30/08/2025
Treatment of Complicated Staphylococcus aureus Bacteremia 13/08/2025
From the JAMA Network: Incidence and Nature of Antidepressant Discontinuation Symptoms 05/08/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 28/07/2025
Life Support and Outcomes in Patients Admitted to Intensive Care Units 14/04/2025
Increases in Invasive Group A Streptococcal Infections 07/04/2025
Preventive Health Care Among Adults Eligible for Lung Cancer Screening 02/04/2025
Cardiac Arrests During Long-Distance Running: What’s Changed? 30/03/2025
Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS) 18/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA